Commenting on the Group’s performance in the first quarter, Roche CEO Severin Schwan said: “In 2021, Roche remains strongly committed to the fight against COVID-19. The uptake of our recently introduced diagnostic tests and medicines remains strong, while we continue to see the expected impact from biosimilars on sales of our established medicines. Our broad product pipeline keeps making good progress. I am particularly pleased about the highly encouraging study results of our immunotherapy Tecentriq in early lung cancer and of faricimab in ophthalmology. The upcoming acquisition of GenMark underlines our commitment to help control infectious diseases and antibiotic resistance. Based on the results of the first quarter of 2021, we confirm the outlook for the full year.”
Commenting on the Group’s performance in the first quarter, Roche CEO Severin Schwan said:
“In 2021, Roche remains strongly committed to the fight against COVID-19. The uptake of our recently introduced diagnostic tests and medicines remains strong, while we continue to see the expected impact from biosimilars on sales of our established medicines. Our broad product pipeline keeps making good progress. I am particularly pleased about the highly encouraging study results of our immunotherapy Tecentriq in early lung cancer and of faricimab in ophthalmology. The upcoming acquisition of GenMark underlines our commitment to help control infectious diseases and antibiotic resistance. Based on the results of the first quarter of 2021, we confirm the outlook for the full year.”
Group sales increase 3%
1 at constant exchange rates (CER); 1% decline in Swiss francs, as a result of the appreciation of the Swiss franc
Pharmaceuticals Division sales: As expected, significant impact from biosimilars (CHF -1.6 billion) Base effect from the strong first quarter 2020 (negative impact of the pandemic only since April 2020) Overall, this results in a 9% decline in sales.
Diagnostics Division sales:
Roche s contributions to the fight against the COVID-19 pandemic in the first quarter: SARS-CoV-2 Rapid Antigen Test Nasal to quickly identify people with the highest risk to be infectious (using simple nasal swabs) receives CE mark and special approvals for self-testing in several countries
Roche Stock Up On Higher Q1 Sales At Constant Rates; Backs FY21 Outlook
SOUTH SAN FRANCISCO (dpa-AFX) - Shares of Roche were gaining around 2 percent in Swiss trading after the drug major reported Wednesday a 3 percent rise in first-quarter sales at constant currency basis mainly driven by strong growth in Diagnostics Division. Sales, on a reported basis, edged down 1 percent mainly with significant impact from biosimilars.
Looking ahead for fiscal 2021, the company continues to expect sales to grow in the low- to mid-single digit range, at constant exchange rates, despite the continued strong impact of biosimilars.
Core earnings per share are still targeted to grow broadly in line with sales, at constant exchange rates.
F Hoffmann-La Roche Ltd: Roche reports solid results in the first quarter of 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.